The Durham-Humphrey Amendment, signed October 26, 1951 as Public Law 82-215, amended Section 503(b) of the Federal Food, Drug, and Cosmetic Act to create the legal split between prescription (“legend”) drugs and over-the-counter (OTC) drugs. Before 1951, manufacturers alone decided a drug’s prescription status. The amendment is named for sponsors Senator Hubert Humphrey and Representative Carl Durham.
For research administrators and clinical operations staff, Durham-Humphrey is foundational rather than incidental: it is the statutory basis for why an investigational product’s eventual marketing status (prescription vs. OTC) is a defined regulatory outcome, not just a labeling preference, and it underlies why informed-consent and dispensing-control requirements in a trial protocol track back to a drug’s legal classification.
What the amendment actually did
Durham-Humphrey resolved three specific gaps in the 1938 Act by amending Section 503(b):
- Established two statutory drug categories. It defined criteria under which a drug must be restricted to prescription (legend) status: drugs that are habit-forming, unsafe for use except under a licensed practitioner’s supervision because of their toxicity or other potential for harm, or limited to prescription use as a condition of an approved new drug application. Any drug not meeting those criteria could be sold OTC.
- Required the prescription legend. Drugs classified as prescription-only had to bear the statement: “Caution: Federal law prohibits dispensing without a prescription” — the origin of the term “legend drug.”
- Legalized oral prescriptions and authorized refills. Before 1951, the statutory basis for a pharmacist accepting a verbal order from a physician, or refilling a prescription without a new written order each time, was unclear. The amendment explicitly permitted both, provided the oral order was promptly reduced to writing and refills were authorized by the prescriber.
Why the distinction was needed
The 1938 FD&C Act was passed primarily in response to the 1937 Elixir Sulfanilamide poisonings, and its central concern was labeling adequacy and premarket safety review, not access control. It required “adequate directions for use” on drug labels but did not resolve what happened when a drug genuinely could not be used safely without a clinician’s involvement — a tranquilizer or antibiotic, for instance, where lay self-directed use posed real risk regardless of how thoroughly it was labeled. Manufacturers were, in practice, free to decide for themselves whether a given drug needed a prescription, which produced inconsistent classification across similar products and left FDA without a clear statutory hook to require prescription status where it was clinically warranted. Durham-Humphrey gave FDA that authority directly, converting an inconsistent industry practice into an enforceable federal standard.
How it fits into the broader history of FDA drug regulation
Durham-Humphrey sits between two other landmark amendments that research administrators are more likely to encounter directly in day-to-day regulatory work, and understanding the sequence clarifies what each one actually governs:
- 1938 — Federal Food, Drug, and Cosmetic Act. Established premarket safety review and labeling requirements, but no prescription/OTC classification system.
- 1951 — Durham-Humphrey Amendment. Created the prescription vs. OTC distinction described above.
- 1962 — Kefauver-Harris Amendment. Passed in response to the thalidomide crisis, this added the requirement that new drugs demonstrate efficacy, not just safety, before approval, and introduced the modern Investigational New Drug (IND) framework and formal informed-consent requirements for clinical investigations — the direct regulatory ancestor of today’s IND/clinical-trial authorization process.
- 1972 onward — the OTC Drug Review. FDA used its Durham-Humphrey authority as the basis for a systematic, ingredient-by-ingredient review of nonprescription drugs, evaluating them for safety, efficacy, and appropriate labeling under expert advisory panels — the process that eventually produced the OTC drug monograph system.
- Rx-to-OTC switch process. The same statutory framework Durham-Humphrey created is what FDA still uses to evaluate whether a drug’s approved prescription status can be switched to OTC once post-marketing experience shows it can be used safely and effectively without practitioner supervision — the mechanism behind switches such as ibuprofen, loratadine, and omeprazole moving from prescription to OTC status over time.
Relevance to clinical research administration today
Although Durham-Humphrey itself predates the modern clinical-trials regulatory apparatus by more than a decade, the Rx/OTC classification it created is still an active input into trial design and administration:
- Investigational drug dispensing control. An investigational product administered under an IND is, by definition, restricted to use under the investigator’s supervision per the protocol — the same underlying logic (practitioner-controlled access for a product whose safety profile isn’t yet fully established) that Durham-Humphrey codified for approved drugs.
- Comparator and background-therapy selection. Whether a comparator or concomitant medication used in a trial is legally available OTC or requires a prescription affects consent language, dispensing logs, and drug-accountability procedures at the site level.
- Rx-to-OTC switch studies. A specific category of clinical trial exists solely to generate the “actual use” and label-comprehension data FDA requires to support a switch application — these trials are designed around demonstrating that a consumer can select and use the product appropriately without a clinician, directly testing the Durham-Humphrey-era safety rationale for prescription status in reverse.
- Regulatory history literacy. Auditors, IRB/ethics reviewers, and new research administrators are frequently expected to place later frameworks — the IND process, GCP, informed consent — in their historical context; Durham-Humphrey is one of the standard reference points in that history alongside the 1938 Act and Kefauver-Harris.
Frequently asked questions
What is a “legend drug”?
A legend drug is a prescription drug — the term comes directly from the Durham-Humphrey Amendment’s requirement that such drugs carry the label statement (the “legend”) “Caution: Federal law prohibits dispensing without a prescription.” The term is still in common pharmacy and regulatory use today.
Is the Durham-Humphrey Amendment still in effect?
Yes. It remains part of the FD&C Act (codified within 21 U.S.C. § 353, the current location of amended Section 503(b)), and the prescription/OTC classification system it created is still the operative framework FDA uses, though the specific criteria and processes around it — particularly the OTC drug review and monograph system — have been refined by subsequent legislation and rulemaking. Most significantly, the 2020 CARES Act added Section 505G to the FD&C Act, replacing the old notice-and-comment rulemaking process for OTC monographs with a streamlined FDA administrative-order process funded by a new OTC monograph drug user-fee program.
How is Durham-Humphrey different from the Kefauver-Harris Amendment?
Durham-Humphrey (1951) created the prescription vs. OTC distinction and legalized refills and oral prescriptions. Kefauver-Harris (1962) is a separate, later amendment that added the requirement that drugs demonstrate efficacy (not just safety) before approval and established the modern framework for investigational new drug review and informed consent in clinical investigations. They address different problems and are often confused because both are mid-century amendments to the same 1938 Act.
Who sponsored the amendment, and why is it named that way?
It is named for its two congressional sponsors: Senator Hubert H. Humphrey Jr. of Minnesota, later U.S. Vice President, and Representative Carl Durham of North Carolina. Both were trained pharmacists before entering Congress, which is part of why the bill’s drafting reflected practical dispensing concerns — verbal orders and refills — alongside the classification question.
Did Durham-Humphrey create the FDA’s authority to require clinical trials?
No. That authority developed separately, primarily through the 1962 Kefauver-Harris Amendment and its IND framework. Durham-Humphrey’s scope is narrower: it governs how an already-marketed drug is classified for dispensing purposes, not the premarket testing pathway a new drug must go through.
See also CASRAI’s broader clinical research administration hub for related regulatory and trial-operations topics.
